Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Single Arm Trial to Characterize Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus After Failure of the First VEGF-targeted Therapy

NCT01266837 is registered in ClinicalTrials.gov with iOMEDICO AG as lead sponsor.

NCT NCT01266837
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01266837 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Single Arm Trial to Characterize Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus After Failure of the First VEGF-targeted Therapy
Lead sponsor
iOMEDICO AG
Phase
Phase 4
Overall status
Completed
Start date
March 31, 2011
Completion date
October 31, 2017
Enrollment
64 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

failure of exactly one prior vegf-targeted therapy, metastatic renal cell carcinoma